Search Results

750 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, IGPOST 01; CORESTA Meeting, Agronomy/Phytopathology, 2023, Cancun, IGPOST 01 (also presented at TSRC 2023)

    CORESTA strategy, cooperation and achievements

    LINDHOLM J.(1); DIGARD H.(2); STEVENS R.(3); COLARD S.(4)
    (1) Swedish Match AB, Stockholm, Sweden; (2) BAT Investments Limited, R&D Centre, Southampton, U.K.; (3) RAI Services Company, Winston Salem, NC, U.S.A.; (4) CORESTA, Paris, France
    The mission of CORESTA is to promote and facilitate international cooperation and best practices in scientific research relative to tobacco and its derived products. Solidly based governance rules are defined and published to optimally fulfil this...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, NAM 00

    New Approach Methods (NAMs) Symposium-II: Applications in Tobacco Regulatory Sciences

    LEE K.M.(1); SIMMS L.(2)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Imperial Brands PLC, Bristol, U.K.
    New Approach Methods (NAMs) in toxicology refer generally to in vitro and in silico or computational methodologies that, without additional in vivo animal testing, could enable clinically relevant toxicological risk assessment. At CORESTA...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, NAM 01

    The use of NAMs in in vitro genotoxicity assessment of nicotine delivery products: ToxTracker assay as a case study

    BREHENY D.(1); LEVERETTE R.(2)
    (1) BAT Investments Limited, R&D Centre, Southampton, U.K.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.
    Genotoxicity and cytotoxicity assessments are an indispensable component in the safety assessment of tobacco and nicotine delivery products. They also form a cornerstone of the preclinical component of regulatory dossiers. In the case of...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, NAM 03

    Exposure to fresh whole smoke and aerosols: standard and novel (3D) in vitro models

    POUR S.J.(1); SIMMS L.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Imperial Brands PLC, Bristol, U.K.
    New Approach Methods (NAMs) describe non-animal- based methodologies that enable more human relevant toxicological risk assessments. In this talk, regulatory in vitro toxicology assays (CORESTA battery) are refined for NGP (Next Generation Product)...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, NAM 04

    EpiAirway Nrf2 – oxidative stress model: Practical application of in vitro systems with clinical relevance

    KEYSER B.M.(1); WERTMAN J.(1); HOLLINGS M.(2); JORDAN K.(1)
    (1) Scientific & Regulatory Affairs, RAI Services Company, Winston Salem, NC, U.S.A.; (2) Labcorp Early Development Laboratories Ltd, Harrogate, U.K.
    The nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway regulates genes that contribute to the antioxidative stress response. This pathway is involved in respiratory diseases, including chronic obstructive pulmonary disease (COPD)....
  6. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, ST 05

    A quantitative risk assessment approach to compare toxic emissions of electronic cigarettes with combustible cigarettes

    LIU C.(1); BERNAL A.J.(2); HUANG Yilang(3); LIU Chuan(4); GRAFF D.W.(1); JIAN Xingtao(3)
    (1) RiskWise Solution LLC, Princeton, NJ, U.S.A.; (2) ToxCreative LLC, Laguna Hills, CA, U.S.A.; (3) RELX Technology, RELX International, Shenzhen, China; (4) Pinevale Ltd, Southampton, U.K.
    Electronic cigarettes (e-cigarettes) heat a nicotine-containing e-liquid that could significantly reduce the number and levels of inhaled toxicants compared to combustible cigarette smoke. A framework for analytical evaluation of the e-cigarette...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, ST 18

    An adverse outcome pathway for oxidative stress in plaque formation

    MAKENA P.(1); HASWELL L.(2); McEWAN M.(2); KEYSER B.M.(1); SMART D.(2); LEVERETTE R.(1); JORDEN K.(1); BREHENY D.(2); BAXTER S.A.(2)
    (1) RAI Services Company, Winston Salem, NC, U.S.A.; (2) BAT Investments Limited, R&D Centre, Southampton, U.K.
    Adverse outcome pathways (AOPs) have been developed as risk assessment tool for regulatory applications. These AOPs describe a logical mechanistic sequence of events, starting with a Molecular Initiating Event (MIE), and ultimately leading to a...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, ST 25 (also presented at TSRC 2023)

    Switching exclusively from smoking to using glo results in significant, substantial reductions in exposure to cigarette smoke toxicants

    GALE N.; AZZOPARDI D.; McEWAN M.; MEICHANETZIDIS F.; VEL S.
    BAT Investments Limited, R&D Centre, Southampton, U.K.
    For those who would not otherwise quit smoking, a proposed tobacco harm reduction approach relies on the proposition that the health burden of smoking can be reduced by encouraging smokers to switch to alternative products that, while not being risk...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, STPOST 07

    In vitro cytotoxicity and mechanistic insight from MucilAir™ and SmallAir™ tissues exposed to cigarette smoke and next-generation products

    HOLLINGS M.(1); ROTHWELL E.(1); MARTIN S.(1); DAUNT A.(1); FREIBERG G.(2); BEDFORD R.(1)
    (1) Labcorp Early Development Laboratories Ltd., Harrogate, U.K.; (2) Labcorp Early Development Laboratories Ltd., Eye, U.K.
    There is a current push to investigate emerging Next Generation Products (NGPs) including Electronic Nicotine Delivery System (ENDS) and Heated Tobacco Products (HTPs). 3D airway tissue models are a relevant method for analysis of toxicity for these...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, STPOST 10

    In vitro micronucleus in V79 cells using Microflow - treatment at the air liquid interface with aerosol from three different nicotine containing products

    ROTHWELL E.; SMITH G.; MARTIN S.; HOLLINGS M.
    Labcorp Early Development Laboratories Ltd, Harrogate, U.K.
    The in vitro micronucleus assay is a standard genetic toxicology test. Historically this has been run with a slide scoring endpoint which is labour intensive and low throughput for testing multiple products. Flow cytometer analysis can be performed,...